Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Breast Cancer: early-phase trial registry
18 of 29 indexed Advanced Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #552 of 28,707 conditions by registered trial count.
29 US clinical trials · 18 currently recruiting · #552 of 28,707 conditions by registered trial count
Advanced Breast Cancer: 29 US clinical trials tracked, 18 recruiting.
Advanced Breast Cancer is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 18 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most active sponsor is Relay Therapeutics, running 3 of these trials.
Enrollment posture brief
Registry condition advanced-breast-cancer
OPEN 18 | RECR 62% | LATE 4 | EARLY 20 | RANK #552 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Gastrointestinal Cancer (62% recruiting · 50 trials)
Advanced Breast Cancer lists 18 open slots (62% of 29 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Breast Cancer is recruiting above its size-band peers.
18 of 29 indexed trials (62.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Advanced Breast Cancer trials is spread across many organizations.
Relay Therapeutics accounts for 3 of 29 trials (10.3%). 24 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced Breast Cancer enrolment sits around 200 participants.
Median target enrolment is 200 among the 29 trials that report a genuine target (sentinel values excluded). 8 of those (27.6%) plan for fewer than 100 participants.
-
Advanced Breast Cancer research is mostly interventional.
28 interventional and 1 observational studies make up this index (96.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
29 total, page 1 of 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Relay Therapeutics
NCT05216432
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Relay Therapeutics
NCT06982521
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Olema Pharmaceuticals
NCT06016738
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
AstraZeneca
NCT06380751
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT06625775
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeiGene
NCT06120283
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Pfizer
NCT07318805
Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer
University of Miami
NCT06123988
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Stemline Therapeutics
NCT06638307
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
NCT06997029
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
NCT06993844
The COMPASSION Study
Dana-Farber Cancer Institute
NCT06507930
Engage Psychosocial Intervention for Cancer Symptoms
Duke University
NCT06555588
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06157892
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
Dartmouth-Hitchcock Medical Center
NCT05933395
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT04222413
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
Boundless Bio
NCT07408089
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
Reshma L. Mahtani, D.O.
NCT06263543
Emulation of the PALOMA-2 Trial
Brigham and Women's Hospital
NCT07178743
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
Pfizer
NCT05654623
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Eli Lilly and Company
NCT04188548
RCT of CBD for Anxiety in Advanced Breast Cancer
Dana-Farber Cancer Institute
NCT04482244
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
Carey Anders, M.D.
NCT05323955
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
RayzeBio
NCT06590857
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
Astellas Pharma Global Development
NCT02091960
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
Bristol-Myers Squibb
NCT00754325
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
Relay Therapeutics
NCT05759949
Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer
Case Comprehensive Cancer Center
NCT01876238
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
Abramson Cancer Center at Penn Medicine
NCT03685331
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 7 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Breast Cancer page
29 registered trials, 18 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 18 Advanced Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Relay Therapeutics sponsors the most Advanced Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Relay Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Breast Cancer condition card totals 29 registered trials; most-linked intervention Fulvestrant; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.